Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study

Experimental and Therapeutic Medicine

Volumn 2, Issue 5, 2011, Pages 859-866

  Blane Schilling, M ^a   Parks, Connie ^a   Deeter, Robert G ^b  

^a Aspen Healthcare Metrics   (United States)

^b AMGEN INC   (United States)

Author keywords

Complications; Cost; Neutropenia

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; FEMALE; FEVER; HOSPITAL PATIENT; HOSPITALIZATION COST; HUMAN; INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NEUTROPENIA; OUTCOMES RESEARCH; REIMBURSEMENT; RETROSPECTIVE STUDY;

EID: 79960239475     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.312     Document Type: Article

References (24)

1. Kuderer NM, Dale DC, Crawford J, et al: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106: 2258-2266, 2006.
2. Link BK, Budd GT, Scott S, et al: Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 92: 1354-1367, 2001.
3. Adida C, Haioun C, Gaulard P, et al: Prognostic significance of surviving expression in diffuse large B-cell lymphomas. Blood 96: 1921-1925, 2000.
4. Lyman GH, Dale DC and Crawford J: Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21: 4524-4531, 2003.
5. Hryniuk WM: Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14: 65-74, 1987.
6. Klastersky J, Paesmans M, Rubenstein EB, et al: The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18: 3038-3045, 2000.
7. Talcott JA, Siegel RD, Finberg R and Goldman L: Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 110: 316-322, 1992.
8. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24: 3187-3205, 2006.
9. Bonadonna G, Moliterni A, Zambetti M, et al: 30 years' follow up of randomized studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330: 217, 2005.
10. Epelbaum R, Faraggi D, Ben-Arie Y, et al: Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 66: 1124-1129, 1990.
11. Kwak LW, Halpern J, Olshen RA and Horning SJ: Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8: 963-977, 1990.
12. Lepage E, Gisselbrecht C, Haioun C, et al: Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol 4: 651-656, 1993.
13. Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M and Oster G: Cost of neutropenic complications of chemotherapy. Ann Oncol 19: 454-460, 2008.
14. Caggiano V, Weiss RV, Rickert TS and Linde-Zwirble WT: Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103: 1916-1924, 2005.
15. Health Insurance Portability and Accountability Act of 1996, 42 USC, pp1320-1322, 1996.
16. US Dept of Health and Human Services: Public Welfare-Protection of Human Subjects, 45 CFR 46. www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm. Accessed Aug 12, 2009.
17. Weycker D, Malin J, Kim J, et al: Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 31: 1069-1081, 2009.
18. Gold M, Siegel JE, Russell LB and Weinstein MC: Cost-Effectiveness in Health and Medicine. Oxford University Press, New York, pp91-92, 1996.
19. Center for Medicare and Medicaid Services: Eliminating serious, preventable, and costly medical errors-never events, CMS Fact Sheet, May, 18, 2006. www.cms.hhs.gov/apps/media/press/factsheet.asp?Counter=1863&intNumPerPage=10&checkDate=&checkKey=&srchType=1&numDays=3500&srchOpt=0&srchData=&keywordType=All&chkNewsType=6&intPage=&showAll=&pYear=&year=&desc=false&cboOrder=date. Accessed Oct 5, 2009.
20. National Comprehensive Cancer Network clinical practice guidelines in oncology: Myeloid growth factors in cancer treatment, version 2.2005 [online]. www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf.2005. Accessed Mar 12, 2009.
21. Glaspy J, Hackett J, Flyer P, et al: Febrile neutropenia is associated with an increase in the incidence, duration, and severity of chemotherapy toxicities. Blood 98: 432b, 2001.
22. Brown RE, Hutton J and Burrell A: Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 19: 1091-1102, 2001.
23. Fortner BV, Stolshek B, Tauer KW, et al: Final analysis: chemotherapy-induced neutropenia (CIN) is associated with lower quality of life (QoL) in patients (pts) with cancer. Ann Oncol 13 (Suppl 15): 174, 2002.
24. Okon TA, Fortner BV, Schwartzberg L, et al: Quality of life (QOL) in patients with grade IV chemotherapy-induced neutropenia (CIN). Proc Am Soc Clin Oncol 21: 275b, 2002.